Pregnancy

Research on outcomes of pregnancy for women with chronic fatigue syndrome is limited.

There is some evidence of symptom improvement or remission in various inflammatory and autoimmune diseases during pregnancy. This may be due to hormonal or immune changes.

Development of the placenta
The placenta is a vascular organ that develops during pregnancy, attaching to the wall of the uterus. The umbilical cord connects the placenta to the developing fetus, allowing for blood to pass from the mother. The placenta allows for nutrient supply, thermoregulation, waste elimination, and gas exchange for the developing fetus, as well as production of hormones that support pregnancy for the mother. Towards the end of the pregnancy, the placenta provides antibodies to the fetus for postpartum protection.

The fetus and the placenta may be detected as foreign allograft by the mother's immune system. To prevent this from happening, the placenta secretes molecules containing Neurokinin-B. This is the same mechanism that parasitic nematodes use to evade detection by the host immune system. Additionally, there is a presence of lymphocytic suppressor cells in the fetus, which can inhibit maternal cytotoxic T cells.

Immune system
As a prerequisite for a successful pregnancy, the immune system undergoes changes so that the mother's body will not reject the fetus. One study has shown that T cells from pregnant women produce less TH1 cytokines and more TH2 cytokines, indicating a general shift toward the TH2 anti-inflammatory state. In contrast, the T cells in women with recurrent spontaneous abortions produce normal, non-pregnancy levels of TH1 and TH2 cytokines, indicating a shift towards the TH1 pro-inflammatory state in unsuccessful pregnancies. (Many spontaneous abortions are similar to organ transplant rejections.) Additionally, levels of Tregs, progesterone, and estrogen increase during pregnancy, which have anti-inflammatory properties.

Fertility
Women with chronic fatigue syndrome report higher rates of polycystic ovarian syndrome (PCOS) and anovulatory cycles, higher rates of dysmenorrhea and higher rates of endometriosis.

Symptoms during pregnancy
There has been very little research on pregnancy and ME/CFS. One retrospective survey found that 41% of respondents reported no change in symptoms during pregnancy, 30% improved and 39% got worse.

In clinical practice, Dr. Nancy Klimas, Dr. Lucinda Bateman, and Dr. Charles Lapp report higher rates of improvement or remission during pregnancy. Klimas reports that in the 20 women she has followed through pregnancy, improvement in symptoms during pregnancy was "almost universal" and in some cases resulted in total temporary remission. Dr. Lapp reported that 25 out of 27 patients in his practice felt better during pregnancy. Dr. Klimas suggests that improvement may be due to increased blood volume during pregnancy or hormonal changes.

Postpartum
In one survey, after delivery, 30% had no change in symptoms, 20% improved, and 20% got worse. Dr. Klimas reports that her patients typically do well postpartum until about 3 to 6 months after at which time there is often a severe relapse. Another study indicates that postpartum relapse or worsening of symptoms is likely due to the extra effort of taking care of a baby, as well as the shift away from pregnancy-related hormones and the TH2 state.

Postpartum depression is two to three times more common in mothers with ME/CFS compared to healthy mothers.

Complications
When comparing these women's pregnancies after illness onset to pregnancies before illness onset (but not to healthy controls), the rate of complications were similar. In pregnancies occurring after illness onset, there was a higher rate of miscarriages (30% vs. 8%) and development delays or learning disabilities (21% vs. 8%). However, this may be explained by maternal age (pregnancies before illness onset occurred when women were younger than pregnancies occurring after illness onset).

Schacterle and Komaroff (2004)
Schacterle and Komaroff (2004) conducted a retrospective study on women with ME/CFS who had undergone pregnancy before and/or after onset of illness. Many women with ME/CFS have to make the difficult decision of whether to have a child, and concern due to illness has resulted in lower rates of pregnancy. Of interest, "women who had children before the onset of CFS and decided to continue to have children had more pregnancies after the onset. Among the 19 patients (22%) who reported pregnancies both before and after the onset of CFS, 30 pregnancies occurred before and 46 occurred after the onset."

The study showed that during pregnancy, symptoms were unchanged or improved in 71% of women with ME/CFS. After pregnancy, symptoms were unchanged or improved in 50% of patients. Many women report concern over adverse outcomes for their children, yet there is little evidence that this occurs. Importantly, most maternal and offspring outcomes from pregnancies that occurred after illness onset were not systematically worse than pregnancies occurring prior to illness onset. These data are overall encouraging for women with ME/CFS considering pregnancy.

Pregnancy in other conditions
In general, Th1 dominant immune disorders tend to improve during pregnancy while Th2 dominant immune disorders tend to worsen. For example, in a study of women with rheumatoid arthritis 75% of patients experienced remission of their RA during pregnancy and 62% experienced a worsening of symptoms after delivery. 92% relapse within the first three months after delivery. The course of Crohn's disease and ulcerative colitis improves during and after pregnancy. In relapsing-remitting multiple sclerosis, rates of relapse decrease during the first two trimesters and increase significantly postpartum.

By contrast, pregnancy increases rates of lupus flares. In a retrospective study of fibromyalgia patients based on personal interviews, nearly all patients surveyed experienced a worsening of symptoms during pregnancy, especially during the third trimester. Fibromyalgia did not appear to have an adverse effect on the outcome of pregnancy or the health of the baby.

Human Placental Extract
HPE is used as a type of Complementary and Alternative Medicine therapy in various conditions involving chronic inflammation for its anti-inflammatory properties. In one interventional trial, injections of subcutaneous human placental extract (HPE) were found to improve symptoms in ME/CFS patients. Of note, the study did not find a difference between HPE injections and placebo.

Learn more

 * Pregnancy, Motherhood, Parenthood and ME/CFS
 * 2010, Pregnancy in Women with Chronic Fatigue Syndrome (ME/CFS)
 * 2016, Pregnancy and ME/CFS
 * Pregnancy and Chronic Fatigue Syndrome-- Four Mothers Who've Been Through It Talk